Company profile: Vivace Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule YAP-TEAD transcription activity inhibitors targeting the Hippo-YAP pathway for cancer treatment, with a focus on Hippo-YAP pathway research to discover and develop cancer therapeutics.
Products and services
- YAP-TEAD transcription activity inhibitors: Pathway-specific small-molecule medicines engineered to suppress YAP-TEAD transcriptional activity within the Hippo-YAP pathway, aiming to treat cancers driven by dysregulated cell proliferation
- Hippo-YAP pathway research: Mechanism-focused research program characterizing Hippo-YAP signaling roles in cell proliferation and cancer to support development of therapeutics targeting YAP-TEAD transcription activity
- Cancer therapeutics discovery and development: Novel-pathway-targeted programs that discover and develop oncology medicines by focusing on pathway biology to create products for cancer treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vivace Therapeutics
Apeiron Biologics
HQ: Austria
Website
- Description: Provider of discovery and development of novel cancer immunotherapies, with products including Qarziba (cancer immunotherapy, licensed to EUSAPharma), APN401 (first-in-class autologous cell therapy inhibiting the immune checkpoint Cbl-b using RNAi to treat solid tumors), and APN01 (inhaled treatment in clinical trials targeting SARS-CoV-2 in the respiratory tract).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apeiron Biologics company profile →
CEL-SCI
HQ: United States
Website
- Description: Provider of immunotherapy products and technology targeting cancer and infectious diseases, including Multikine, an investigational therapy for advanced primary head and neck cancer intended for use before any other therapy; LEAPS, a platform with candidates for rheumatoid arthritis and other autoimmune and infectious diseases; and a global Phase III trial of Multikine aiming to support potential FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CEL-SCI company profile →
Affiris
HQ: Austria
Website
- Description: Provider of tailor-made peptide vaccines and specific active immunotherapies for chronic diseases, including Alzheimer’s, Parkinson’s, atherosclerosis/hypercholesterolemia and hypertension. Portfolio includes AFFITOPE PD01/PD03 targeting alpha-synuclein, AFFITOPE AT04/AT06 targeting PCSK9 to lower LDL, mAB C6-17 for mutant huntingtin, and the SAIT modality.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affiris company profile →
Acceptys
HQ: United States
Website
- Description: Provider of human antibody therapies targeting cancer and infectious diseases, offering anti-cancer and anti-viral human antibodies for lung, pancreatic, gastric, and colon cancers. Founded in 2002 and based in Sparta, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acceptys company profile →
Sensei Bio
HQ: United States
Website
- Description: Provider of next-generation cancer immunotherapies from a clinical-stage biotechnology company, including SNS-101, a pH-sensitive monoclonal antibody that selectively targets and inhibits VISTA in the acidic tumor microenvironment to enhance T-cell activation and reduce immune suppression, and the TMAb platform for conditionally active antibodies that activate in low-pH tumors to minimize off-tumor activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensei Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vivace Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vivace Therapeutics
2.2 - Growth funds investing in similar companies to Vivace Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vivace Therapeutics
4.2 - Public trading comparable groups for Vivace Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →